Assessing Safety of the Transition to Generic Imatinib in Patients with Gastrointestinal Stromal Tumours
The transition to generic imatinib in Dutch patients with GIST was safe. After switching to generic imatinib, up to 34.6% of patients experienced new AEs, compared with 21.3% in the reference group, indicating that many AEs may have been mistakenly attributed to the switch. The small increase in AEs that we found was unlikely due to pharmacokinetics or excipients. Therefore, we argue that the nocebo effect, where negative expectations about treatment lead to worsened symptoms, played a large role.
Authors
- Alwin D. R. Huitema (ORCID: https://orcid.org/0000-0003-1939-4639)
- Anna K.L. Reyners (ORCID: https://orcid.org/0000-0003-1678-7816)
- Hans Gelderblom
- Evelyne Roets (ORCID: https://orcid.org/0000-0001-9733-7619)
- Ingrid M.E. Desar (ORCID: https://orcid.org/0000-0003-0945-8299)
- Renaud Tissier
- Neeltje Steeghs
- Dorieke E M van Balen
- Maud B. A. van der Kleij (ORCID: https://orcid.org/0009-0008-8492-8039)
- Joris M van Sabben
Institutions
- University Medical Center Groningen (NL)
- Radboud University Nijmegen (NL)
- Utrecht University (NL)
- Leiden University Medical Center (NL)
- Radboud University Medical Center (NL)
- The Netherlands Cancer Institute (NL)
- University Medical Center Utrecht (NL)
- Oncode Institute (NL)
- Princess Máxima Center (NL)
- Erasmus MC Cancer Institute (NL)
Publication Details
- Journal
- Oncology and Therapy
- Published
- 2025-07-01
- DOI
- https://doi.org/10.1007/s40487-025-00353-3
- Primary Topic
- Gastrointestinal Tumor Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00